Detail akcie RepliCel Life Scien online

Business Summary: Replicel Life Sciences Inc is a Canada-based regenerative medicine company. It develops autologous cell therapies that treat functional cellular deficits. Its product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse. RCH-01 also utilizes dermal sheath cup cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to control intradermal (dermis), subcutaneous (fat) or intramuscular injections. It is designed to support the injection of RCH-01 and RCS-01 cell therapy products. The injector has applications for dermatological procedures requiring injections of specific volumes of material at specific depths, including cellular products, fillers and collagen injections.
Financial Summary: BRIEF: For the nine months ended 30 September 2019, RepliCel Life Sciences Inc revenues increased from C$0K to C$189K. Net loss increased 26% to C$2.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from C$454K to C$1.9M (expense), Foreign exchange gain (loss) increase of 16% to C$14K (expense).